Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inadequate antimicrobial treatment is an independent determinant of hospital mortality, and fungal bloodstream infections are among the types of infection with the highest rates of inappropriate initial treatment. Because of significant potential for reducing high mortality rates, we sought to assess the impact of delayed treatment across multiple study sites. The goals our analyses were to establish the frequency and duration of delayed antifungal treatment and to evaluate the relationship between treatment delay and mortality. METHODS: We conducted a retrospective cohort study of patients with candidemia from 4 medical centers who were prescribed fluconazole. Time to initiation of fluconazole therapy was calculated by subtracting the date on which fluconazole therapy was initiated from the culture date of the first blood sample positive for yeast. RESULTS: A total of 230 patients (51% male; mean age +/- standard deviation, 56 +/- 17 years) were identified; 192 of these had not been given prior treatment with fluconazole. Patients most commonly had nonsurgical hospital admission (162 patients [70%]) with a central line catheter (193 [84%]), diabetes (68 [30%]), or cancer (54 [24%]). Candida species causing infection included Candida albicans (129 patients [56%]), Candida glabrata (38 [16%]), Candida parapsilosis (25 [11%]), or Candida tropicalis (15 [7%]). The number of days to the initiation of antifungal treatment was 0 (92 patients [40%]), 1 (38 [17%]), 2 (33 [14%]) or > or = 3 (29 [12%]). Mortality rates were lowest for patients who began therapy on day 0 (14 patients [15%]) followed by patients who began on day 1 (9 [24%]), day 2 (12 [37%]), or day > or = 3 (12 [41%]) (P = .0009 for trend). Multivariate logistic regression was used to calculate independent predictors of mortality, which include increased time until fluconazole initiation (odds ratio, 1.42; P < .05) and Acute Physiology and Chronic Health Evaluation II score (1-point increments; odds ratio, 1.13; P < .05). CONCLUSION: A delay in the initiation of fluconazole therapy in hospitalized patients with candidemia significantly impacted mortality. New methods to avoid delays in appropriate antifungal therapy, such as rapid diagnostic tests or identification of unique risk factors, are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mortality reduction associated with early antimicrobials appears strongest in patients with septic shock, where studies have reported a strong association between time to antibiotics and death in patients with septic shock but weaker associations in patients without septic shock (98,109,110).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [109]
In the citing paper
“Blood cultures take an average of 2–3 days to grow Candida, or longer depending on the species.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Attributable mortality from IC remains high and increases with delays in treatment.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association [167, 171–173].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [171]
In the citing paper
“Multivariate analysis in this study also provided a strong association between delay in therapy and mortality.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [46]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 11×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 2×
“of inappropriate initial treatment [6].”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286 · cited 5×
“Delaying antifungal therapy appears to be a common practice, and the impact on mortality may be significant [8, 10].”
BackgroundResultInfluentialAttributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“Attributable mortality rates of 49% were also shown among patients with candidemia, compared with uninfected control subjects matched for age, sex, date of hospital admission, underlying diseases, length of time at risk, and type of surgical procedure [5].”
BackgroundPfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521 · cited 1×
“[1].”
Morgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437 · cited 2×
“attributable mortality remains 19%–49% [2, 5].”
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 331 · cited 10×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialThe Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“of 8 cases per 100,000 population [2–4].”
Leinberger, D. M., Schumacher, U., Autenrieth, I. B., & Bachmann, T. T. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.4943-4953.2005 · Cited by 170 · cited 1×
“Development of nonculture methods for the rapid diagnosis of candidemia in patients with BSI may also significantly improve the ability to quickly prescribe appropriate antifungal therapy [19, 20].”
Epidemiology and Prognostic Determinants of Bloodstream Infections in Surgical Intensive Care
Harbarth, S., Ferrière, K., Hugonnet, S., Ricou, B., Suter, P., & Pittet, D. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.12.1353 · Cited by 135
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
“mortality [14, 17, 18, 236].”
BackgroundInfluentialPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
“Early initiation of effective antifungal therapy is critical in the successful treatment of candidemia, as demonstrated by recent data suggesting higher mortality rates among patients with candidemia whose therapy was delayed [77, 78].”
BackgroundResultSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956
“Inappropriate therapy or delays in initiation of therapy have also been linked to increased mortality [24, 25].”
BackgroundEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
“…treatment with an agent to which the organism is resistant, inadequate dose or duration of treatment, or no treatment at all (Armstrong-James 2007; Atkinson et al. 2008; Garey et al. 2006; Garey et al. 2007; Klevay et al. 2008; Morgan et al. 2005a; Morrell et al. 2005; Parkins et al. 2007).”
BackgroundInfluentialChamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2008) · Clinical Infectious Diseases · doi:10.1086/590004 · Cited by 826
“Furthermore, 2 recent retrospective cohort studies demonstrated that the early initiation of effective empirical antifungal therapy within 12 h after the first finding of a blood sample positive for Candida infection is critical for a successful outcome among patients with candidemia [15, 16].”
BackgroundAndes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738
Global trends in the distribution of Candida species causing candidemia
Guinea, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12539 · Cited by 680
“The mortality rate is clearly correlated with a delay in the initiation of appropriate antifungal treatment [14,15].”
BackgroundResistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
“Third, recent data support that early treatment of fungal infection with a lower burden of organisms reduces the number of treatment failures [103-105].”
BackgroundPfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
“sooner (30, 48, 54), attention has been focused on the validation of”
BackgroundSeptic shock attributed to Candida infection: Importance of empiric therapy and source control.
Kollef, M., Micek, S., Hampton, N., Doherty, J. A., & Kumar, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis305 · Cited by 477
“not receive prior antifungal therapy [16].”
T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial
Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., Garey, K. W., Alangaden, G. J., Vazquez, J. A., Groeger, J. S., Judson, M. A., Vinagre, Y.-M., Heard, S. O., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu959 · Cited by 443
“This difference in time of identification could impact the mortality of candidemic patients [5, 6].”
Self-citationEstimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438
Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394
PCR Diagnosis of Invasive Candidiasis: Systematic Review and Meta-Analysis
Avni, T., Leibovici, L., & Paul, M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01602-10 · Cited by 389
“5 for death with early antifungal treatment (8, 24, 40, 58, 60, 72).”
BackgroundInvasive candidiasis as a cause of sepsis in the critically ill patient
Delaloye, J., & Calandra, T. (2014) · Virulence · doi:10.4161/viru.26187 · Cited by 372
Perez, K. K., Olsen, R. J., Musick, W. L., Cernoch, P. L., Davis, J. R., Land, G. A., Peterson, L. E., & Musser, J. M. (2013) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2012-0651-oa · Cited by 388
Kett, D. H., Azoulay, E., Echeverria, P. M., & Vincent, J.-L. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318206c1ca · Cited by 389
“Early initiation of adequate antifungal therapy has been shown to improve survival in patients with candidemia (16, 37, 38).”
BackgroundLeón, C., Ruiz-Santana, S., Saavedra, P., Galván, B., Blanco, A., Castro, C., Balasini, C., Utande-Vázquez, A., González de Molina, F. J., Blasco-Navalproto, M. A., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819daa14 · Cited by 375
“85) No (n 248) 3 4 1 0 8 (3,2) Urine Yes (n 228) 17 4 0 0 21 (9.”
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
“These facts are relevant because increased mortality rate is associated with delays in initiating adequate antifungal therapy (Garey et al., 2006; Bassetti et al., 2014).”
BackgroundEpidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Molecular and Nonmolecular Diagnostic Methods for Invasive Fungal Infections
Arvanitis, M., Anagnostou, T., Fuchs, B. B., Caliendo, A. M., & Mylonakis, E. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00091-13 · Cited by 353
Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12040 · Cited by 360
Prevalence of Antimicrobial Use in US Acute Care Hospitals, May-September 2011
Magill, S. S., Edwards, J. R., Beldavs, Z. G., Dumyati, G., Janelle, S. J., Kainer, M. A., Lynfield, R., Nadle, J., Neuhauser, M. M., Ray, S. M., et al. (2014) · JAMA · doi:10.1001/jama.2014.12923 · Cited by 350
“Data Collection Data collectors reviewed medical records on the survey date to determine whether patients may have been receiving enteral (excluding rectal), intravenous, intramuscular, or inhaled antimicrobial drugs (eMethods 1 in the Supplement) at the time of the survey, using the following screening criteria: (1)…”
Tumbarello, M., Posteraro, B., Trecarichi, E. M., Fiori, B., Rossi, M., Porta, R., de Gaetano Donati, K., La Sorda, M., Spanu, T., Fadda, G., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00131-07 · Cited by 343
“Interestingly, two recent studies addressing the effects of delayed treatment for patients with candidemia found that receipt of an antifungal agent 24 h after the blood sample was obtained for culture was associated with an increased risk of mortality (6, 26).”
BackgroundResultInfluentialCommunity-acquired Pneumonia and Hospital-acquired Pneumonia
Lanks, C. W., Musani, A. I., & Hsia, D. W. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.12.008 · Cited by 297
The French Mycosis Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Madec, Y., Denoeud-Ndam, L., Wolff, M., Fontanet, A., Bretagne, S., & Dromer, F. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3408-3 · Cited by 312
“Although numerous other factors not captured here may have influenced the outcome, such as the delayed initiation of adequate antifungal therapy [8, 39, 40], although controversial [16], lack of consideration of antifungal dosing issues [40–42], and inadequate source control as recently emphasized [16], both the stron…”
BackgroundTherapy for fungal diseases: opportunities and priorities
Denning, D. W., & Hope, W. W. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.02.004 · Cited by 314
Organ-Specific Innate Immune Responses in a Mouse Model of Invasive Candidiasis
Lionakis, M. S., Lim, J. K., Lee, C.-C. R., & Murphy, P. M. (2011) · Journal of Innate Immunity · doi:10.1159/000321157 · Cited by 302
“Likewise, our study shows that, in bloodstream-derived brain infection by Candida , microglia appear to be key innate immune effector cells for Candida control, and possibly for preventing neutrophil-induced immunopathology. Because microglia expand locally both by in situ proliferation and recruitment from blood mono…”
BackgroundMultidrug-Resistant Candida haemulonii and C. auris , Tel Aviv, Israel
Ben-Ami, R., Berman, J., Novikov, A., Bash, E., Shachor-Meyouhas, Y., Zakin, S., Maor, Y., Tarabia, J., Schechner, V., Adler, A., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161486 · Cited by 297
“High rates of attributable death have been associated with delayed initiation of appropriate antifungal treatment (3,4).”
BackgroundMcCarty, T. P., & Pappas, P. G. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.013 · Cited by 285
“Data from several retrospective studies suggest that early and effective treatment confers a survival benefit from Candida sepsis.(19,20) Moreover, early identification to the species level facilitates therapeutic decision making based on the likelihood of flu-”
BackgroundA multicenter study of septic shock due to candidemia: Outcomes and predictors of mortality.
Bassetti, M., Righi, E., Ansaldi, F., Merelli, M., Cecilia, T., De Pascale, G., Diaz-Martin, A., Luzzati, R., Rosin, C., Lagunes, L., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3310-z · Cited by 284
“Several studies have shown that inadequate empirical therapy is associated with an increased mortality in patients with candidemia or septic shock due to Candida [16, 18, 19].”
BackgroundResultT2 Magnetic Resonance Enables Nanoparticle-Mediated Rapid Detection of Candidemia in Whole Blood
Neely, L. A., Audeh, M., Phung, N. A., Min, M., Suchocki, A., Plourde, D., Blanco, M., Demas, V., Skewis, L. R., Anagnostou, T., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005377 · Cited by 272
Pfaller, M. A., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.02.016 · Cited by 274
Senn, L., Robinson, J. O., Schmidt, S., Knaup, M., Asahi, N., Satomura, S., Matsuura, S., Duvoisin, B., Bille, J., Calandra, T., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/527382 · Cited by 263
“and high mortality [1,2].”
Epidemiology of Invasive Fungal Disease in Children
Pana, Z. D., Roilides, E., Warris, A., Groll, A. H., & Zaoutis, T. (2017) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix046 · Cited by 260
Review of Rapid Diagnostic Tests Used by Antimicrobial Stewardship Programs
Bauer, K. A., Perez, K. K., Forrest, G. N., & Goff, D. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu547 · Cited by 250
“until candidemia is confirmed [23, 32].”
Candidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260
“23,24 Moreover, early identification to the species level facilitates therapeutic decision making based on the likelihood of fluconazole susceptibility or resistance and allows informed alterations in therapy while awaiting formal antifungal sensitivity data.”
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
“The high pathogen-related mortality, which may approach 50 %, should prompt immediate initiation of therapy in all patients with suspected yeasts in the blood culture, as delays in treatment result in an increased mortality [48, 111].”
BackgroundHöfs, S., Mogavero, S., & Hube, B. (2016) · Journal of Microbiology · doi:10.1007/s12275-016-5514-0 · Cited by 238
“prognosis; mortality rates increase from 15%, when antifungal treatment is initiated immediately after positive blood culture, to 40%, when treatment is delayed by only 72 h (Garey et al., 2006).”
BackgroundPatients at High Risk of Invasive Fungal Infections: When and How to Treat
Rüping, M. J. G. T., Vehreschild, J. J., & Cornely, O. A. (2008) · Drugs · doi:10.2165/00003495-200868140-00002 · Cited by 253
“[126] do not mention speciescandidiasis,[136,137] a basis of evidence for the future specific time to eradication, but no significant difuse of these strategies is an unmet medical need.”
BackgroundESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients
Martin-Loeches, I., Antonelli, M., Cuenca-Estrella, M., Dimopoulos, G., Einav, S., De Waele, J. J., Garnacho-Montero, J., Kanj, S. S., Machado, F. R., Montravers, P., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05599-w · Cited by 235
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01079-10 · Cited by 238
“It is now evident that a delay in initiating antifungal therapy in the critically ill patient is associated with compromised outcomes (an increase in mortality of 8% for each hour in which appropriate therapy is delayed), excessive costs of hospitalization, and potentially devastating complications such as endocarditi…”
BackgroundParkins, M. D., Sabuda, D. M., Elsayed, S., & Laupland, K. B. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm212 · Cited by 229
“Garey et al. 18 further demonstrated in a multicentre retrospective study that for each successive day of delay in receipt of fluconazole treatment there was an increase in patient mortality.”
BackgroundCosta-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
“One of the main factors that contribute to the high mortality rate associated with Candidaemia is the difficulty in diagnosis, due to the nonspecific clinical symptoms of systemic fungal infection and delayed laboratorial detection methods, as well as the subsequent delay in initiation of adequate antifungal therapy […”
BackgroundBader, O., Weig, M., Taverne-Ghadwal, L., Lugert, R., Groß, U., & Kuhns, M. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03398.x · Cited by 227
Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference
Sartelli, M., Catena, F., Abu-Zidan, F. M., Ansaloni, L., Biffl, W. L., Boermeester, M. A., Ceresoli, M., Chiara, O., Coccolini, F., De Waele, J. J., et al. (2017) · World Journal of Emergency Surgery · doi:10.1186/s13017-017-0132-7 · Cited by 199
Mannosylation in Candida albicans: role in cell wall function and immune recognition
Hall, R. A., & Gow, N. A. R. (2013) · Molecular Microbiology · doi:10.1111/mmi.12426 · Cited by 210
“Early detection of invasive candidaemia (IC) is essential for a good prognosis, with mortality rates increasing from 15% (antifungal treatment initiated immediately after positive blood culture), to 40% when treatment is delayed by 72 h (Garey et al., 2006).”
BackgroundBassetti, M., Righi, E., Ansaldi, F., Merelli, M., Scarparo, C., Antonelli, M., Garnacho-Montero, J., Diaz-Martin, A., Palacios-Garcia, I., Luzzati, R., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3866-2 · Cited by 208
“case of Candida septic shock in order to improve patient outcomes [20, 25, 26].”
Bassetti, M., Taramasso, L., Nicco, E., Molinari, M. P., Mussap, M., & Viscoli, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024198 · Cited by 216
“. Certainly the severity of the underlying medical condition greatly influences the crude mortality rate in these patient populations, however for the patient in Internal Medicine inappropriate therapy could represent an important variable – consisting mostly of omission of initial empirical therapy and an inadequate…”
BackgroundMolecular diagnosis of sepsis: New aspects and recent developments
Liesenfeld, O., Lehman, L., Hunfeld, K.-P., & Kost, G. (2014) · European Journal of Microbiology and Immunology · doi:10.1556/eujmi.4.2014.1.1 · Cited by 216
“Increased mortality may also be found following inappropriate fungal therapy [8, 9] since empiric antimycotic coverage is only recommended in high-risk patients (e.”
BackgroundBench-to-bedside review: Candida infections in the intensive care unit
Méan, M., Marchetti, O., & Calandra, T. (2008) · Critical Care · doi:10.1186/cc6212 · Cited by 217
β-Glucan Antigenemia Anticipates Diagnosis of Blood Culture–Negative Intraabdominal Candidiasis
Tissot, F., Lamoth, F., Hauser, P. M., Orasch, C., Flückiger, U., Siegemund, M., Zimmerli, S., Calandra, T., Bille, J., Eggimann, P., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201211-2069oc · Cited by 203
“Admittedly, although the rapid diagnosis of invasive candidiasis is crucial for appropriate management, with an increase in mortality associated with any delay of initiation of therapy (6), this currently eludes us.”
BackgroundSpanu, T., Posteraro, B., Fiori, B., D'Inzeo, T., Campoli, S., Ruggeri, A., Tumbarello, M., Canu, G., Trecarichi, E. M., Parisi, G., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.05742-11 · Cited by 213
“, prompt collection of BCs when BSI is first suspected, immediate transport of cultures to the laboratory), should allow considerably earlier prescription of effective drug therapy for yeast BSIs, with positive effects on patient outcomes (9, 17, 24).”
BackgroundPankla, R., Buddhisa, S., Berry, M., Blankenship, D. M., Bancroft, G. J., Banchereau, J., Lertmemongkolchai, G., & Chaussabel, D. (2009) · Genome Biology · doi:10.1186/gb-2009-10-11-r127 · Cited by 207
“It has been reported that faster diagnosis of other bloodstream infections permits earlier implementation of appropriate antimicrobial therapy and reduces mortality [14].”
BackgroundArendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaldgaard, P., Knudsen, J. D., Kristensen, L., Leitz, C., Lemming, L. E., Nielsen, L., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12212 · Cited by 206
“high mortality in patients in whom antifungal treatment has been delayed [1–8].”
BackgroundTumbarello, M., Fiori, B., Trecarichi, E. M., Posteraro, P., Losito, A. R., De Luca, A., Sanguinetti, M., Fadda, G., Cauda, R., & Posteraro, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033705 · Cited by 197
“The excess of hospital stay attributable to invasive Candida infections has been reported to range from 10 to 30 days in the United States [2], and it could have been underestimated because of the early mortality associated with delayed therapy [7,8].”
BackgroundThompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02324-8 · Cited by 192
Oral candidosis – Clinical challenges of a biofilm disease
Rautemaa, R., & Ramage, G. (2011) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2011.585606 · Cited by 188
“A delay in the initiation of effective antifungal therapy increases mortality in a candidaemia (Morrell et al., 2005; Garey et al., 2006).”
BackgroundPosteraro, B., De Pascale, G., Tumbarello, M., Torelli, R., Pennisi, M. A., Bello, G., Maviglia, R., Fadda, G., Sanguinetti, M., & Antonelli, M. (2011) · Critical Care · doi:10.1186/cc10507 · Cited by 185
“Invasive candidiasis (IC) in non-neutropenic patients admitted to the intensive care unit (ICU) is a serious problem [1-3] and, of particular concern, associated with high mortality [4], especially when prompt and adequate antifungal treatment is not administered [5-8].”
BackgroundColombo, A. L., Guimarães, T., Sukienik, T., Pasqualotto, A. C., Andreotti, R., Queiroz-Telles, F., Nouér, S. A., & Nucci, M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3400-y · Cited by 183
“Delays in initiating antifungal therapy may increase mortality rates in patients with candidemia [7, 8].”
BackgroundIntensive care medicine research agenda on invasive fungal infection in critically ill patients
Bassetti, M., Garnacho-Montero, J., Calandra, T., Kullberg, B., Dimopoulos, G., Azoulay, E., Chakrabarti, A., Kett, D., Leon, C., Ostrosky-Zeichner, L., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4731-2 · Cited by 183
“Various studies have shown that delays in initiating adequate antifungal therapy are associated with increased mortality [12, 13], therefore driving the field to explore advanced strategies such as prophylaxis, markerbased pre-emptive therapy, and risk-based empirical therapy.”
BackgroundInvasive Fungal Infections in the ICU: How to Approach, How to Treat
Paramythiotou, E., Frantzeskaki, F., Flevari, A., Armaganidis, A., & Dimopoulos, G. (2014) · Molecules · doi:10.3390/molecules19011085 · Cited by 175
Benefits and Limitations of MALDI-TOF Mass Spectrometry for the Identification of Microorganisms
Rychert, J. (2019) · Journal of Infectiology · doi:10.29245/2689-9981/2019/4.1142 · Cited by 169
Pfaller, M. A., Castanheira, M., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.06.015 · Cited by 180
“Rapid initiation of appropriate antifungal therapy is essential for the management of IC and has been shown to reduce mortality (Garey et al., 2006; Labelle et al., 2008; Morrell et al., 2005; Parkins et al., 2007).”
BackgroundInvasive Mycoses: Diagnostic Challenges
Ostrosky-Zeichner, L. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.008 · Cited by 176
“The relation between early diagnosis and treatment and mortality was illustrated in a multi-institutional study by Garey et al.(6) of 230 patients with candidemia.”
Treatment-related risk factors for hospital mortality in Candida bloodstream infections
Labelle, A. J., Micek, S. T., Roubinian, N., & Kollef, M. H. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818b3477 · Cited by 181
Antibiotic Exposure as a Risk Factor for Fluconazole-Resistant Candida Bloodstream Infection
Ben-Ami, R., Olshtain-Pops, K., Krieger, M., Oren, I., Bishara, J., Dan, M., Wiener-Well, Y., Weinberger, M., Zimhony, O., Chowers, M., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05947-11 · Cited by 178
“However, given the correlation between the survival rate and the timely initiation of appropriate treatment for candidemia (8), accurate assessment of the risk of fluconazole-resistant Candida (FRC) BSI is of prime importance.”
BackgroundDiagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia
Arendrup, M. C., Sulim, S., Holm, A., Nielsen, L., Nielsen, S. D., Knudsen, J. D., Drenck, N. E., Christensen, J. J., & Johansen, H. K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00179-11 · Cited by 178
“(%) of episodes including bacteria 18 (36) 5 (25) 13 (31) 17 (21) 7 (10) 4 (8) 64 (20) No.”
BackgroundInfluentialSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026
Prescott, H. C., Antonelli, M., Alhazzani, W., Møller, M. H., Alshamsi, F., Azevedo, L. C. P., Belley-Cote, E., De Waele, J., Derde, L., Dionne, J. C., et al. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08361-1 · Cited by 141
Aslam, S., Rotstein, C., & Practice, T. A. I. D. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13623 · Cited by 160
Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis
Pfaller, M. A., & Castanheira, M. (2015) · Medical Mycology · doi:10.1093/mmy/myv076 · Cited by 161
“Treatment of candidiasis is often found to be inadequate based on several factors that may be amenable to antifungal stewardship efforts [10–15,18,20,176].”
BackgroundClancy, C. J., Pappas, P. G., Vazquez, J., Judson, M. A., Kontoyiannis, D. P., Thompson, G. R., Garey, K. W., Reboli, A., Greenberg, R. N., Apewokin, S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1095 · Cited by 165
Self-citationCandidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death
Slavin, M. A., Sorrell, T. C., Marriott, D., Thursky, K. A., Nguyen, Q., Ellis, D. H., Morrissey, C. O., Chen, S. C. A., & on behalf of the Australian Candidemia Study, A. S. F. I. D. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq053 · Cited by 162
Burden of Candidemia in the United States, 2017
Tsay, S. V., Mu, Y., Williams, S., Epson, E., Nadle, J., Bamberg, W. M., Barter, D. M., Johnston, H. L., Farley, M. M., Harb, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa193 · Cited by 163
Pai, M. P., Turpin, R. S., & Garey, K. W. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-06 · Cited by 159
“prescription can impact mortality (10, 20).”
Self-citationColombo, A. L., Guimarães, T., Camargo, L. F. A., Richtmann, R., Queiroz‐Telles, F., Salles, M. J. C., da Cunha, C. A., Shikanai‐Yasuda, M. A., Moretti, M. L., & Nucci, M. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2013.02.001 · Cited by 200
Association of fluconazole pharmacodynamics with mortality in patients with candidemia
Baddley, J. W., Patel, M., Bhavnani, S. M., Moser, S. A., & Andes, D. R. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00116-08 · Cited by 162
“unit, Candida colonization, and previous surgery or antifungal use (8, 9).”
BackgroundT2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis
Pfaller, M. A., Wolk, D. M., & Lowery, T. J. (2015) · Future Microbiology · doi:10.2217/fmb.15.111 · Cited by 167
Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161
Timing of antibiotic therapy in the ICU
Kollef, M. H., Shorr, A. F., Bassetti, M., Timsit, J.-F., Micek, S. T., Michelson, A. P., & Garnacho-Montero, J. (2021) · Critical Care · doi:10.1186/s13054-021-03787-z · Cited by 161
“Regarding other IFIs (e.g. invasive aspergillosis, mucormycosis), no consensus exists about the exact timeframe for starting empirical therapy outside of neutropenic patients [40].”
ResultInfluentialOstrosky-Zeichner, L., Shoham, S., Vazquez, J., Reboli, A., Betts, R., Barron, M. A., Schuster, M., Judson, M. A., Revankar, S. G., Caeiro, J. P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu074 · Cited by 160
“This is also particularly interesting in the face of recent research showing that time to therapy has a definite impact on the outcome of the disease [15] and a proof-of-concept study showing the value of BG-driven therapy [16].”
BackgroundQuantitation of Candida CFU in Initial Positive Blood Cultures
Pfeiffer, C. D., Samsa, G. P., Schell, W. A., Reller, L. B., Perfect, J. R., & Alexander, B. D. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00609-11 · Cited by 158
“Unfortunately, no test has emerged as a clear improvement over blood culture, which remains the standard despite several studies demonstrating need for early therapy to improve outcome (6, 17).”
BackgroundArendrup, M. C., Garcia-Effron, G., Lass-Flörl, C., Lopez, A. G., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01256-09 · Cited by 158
Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp.
Playford, E. G., Marriott, D. J. E., Nguyen, Q. A., Chen, W., Ellis, D., Slavin, M. A., & Sorrell, T. C. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181760f42 · Cited by 175
“Indeed, data suggesting that delayed initiation of antifungal therapy for candidemia is associated with poor clinical outcomes, including increased mortality (6, 7), emphasize the importance of early appropriate antifungal therapy.”
BackgroundShepard, J. R., Addison, R. M., Alexander, B. D., Della‐Latta, P., Gherna, M., Haase, G., Hall, G. S., Johnson, J. K., Merz, W. G., Peltroche‐Llacsahuanga, H., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01385-07 · Cited by 154
“Early and appropriate therapy can critically affect patient outcomes (8); however, antifungal therapy for patients with candidemia is still largely empirical, taking into account patient symptoms, history, and hospital trends.”
BackgroundImpact of Therapeutic Strategies on the Prognosis of Candidemia in the ICU*
Puig‐Asensio, M., Pemán, J., Zaragoza, R., Garnacho‐Montero, J., Martín‐Mazuelos, E., Cuenca‐Estrella, M., & Almirante, B. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000221 · Cited by 167
Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment
Vergidis, P., Clancy, C. J., Shields, R. K., Park, S. Y., Wildfeuer, B. N., Simmons, R. L., & Nguyen, M. H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0153247 · Cited by 150
MALDI ‐ TOF ‐ MS ‐based species identification and typing approaches in medical mycology
Bader, O. (2012) · PROTEOMICS · doi:10.1002/pmic.201200468 · Cited by 148
“Early onset of antifungal therapy is clearly correlated to outcome [91], and the mortality among patients infected with azole nonsusceptible species and receiving inadequate treatment is extremely high [92].”
BackgroundOrtega, M., Marco, F., Soriano, À., Almela, M., Martínez, J. A., López, J. D. S., Pitart, C., & Mensa, J. (2011) · Journal of Hospital Infection · doi:10.1016/j.jhin.2010.09.026 · Cited by 175
Eggimann, P., & Pittet, D. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3355-z · Cited by 159
Das, I., Nightingale, P., Patel, M., & Jumaa, P. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.06.006 · Cited by 158
Systemic antifungal therapy in critically ill patients without invasive fungal infection*
Azoulay, É., Dupont, H., Tabah, A., Lortholary, O., Stahl, J. ‐., Français, A., Martin, C., Guidet, B., & Timsit, J. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e318236f297 · Cited by 148
Antifungal Susceptibility Profile of Cryptic Species of Aspergillus
Alastruey‐Izquierdo, A., Alcázar‐Fuoli, L., & Cuenca‐Estrella, M. (2014) · Mycopathologia · doi:10.1007/s11046-014-9775-z · Cited by 141
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 148
Metadata
- Authors
- Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T.
- Affiliations
- University of Houston (US)
- University of New Mexico (US)
- Baptist Memorial Health Care (US)
- University of Tennessee Health Science Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Oregon State University (US)
- Corresponding author
- Garey, Kevin W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07
- Volume
- 43
- Issue
- 1
- Pages
- 25-31
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2164001967
- Semantic Scholar
- e1a67fd5e540307550577ea7a071370b075e943f
- Cited by
- 1,171
- References
- 20
- Citations by year
- 2026: 31 · 2025: 26 · 2024: 31 · 2023: 31 · 2022: 49 · 2021: 67 · 2020: 51 · 2019: 51 · 2018: 62 · 2017: 66 · 2016: 61 · 2015: 74 · 2014: 87 · 2013: 83 · 2012: 77
- FWCI
- 35.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Enzon Pharmaceuticals
- University of Houston
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, fluconazole, treatment delay, mortality, fungemia, Candida albicans, APACHE II score, mortality risk factors, hospitalized patients, Candida tropicalis, Candida parapsilosis, Candida glabrata, diabetes mellitus, cancer patients, sepsis
- MeSH terms
- Adult, Aged, Antifungal Agents, Candidiasis, Female, Humans, Length of Stay, Male, Middle Aged, Retrospective Studies, Time Factors, Cohort Studies, Fluconazole, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.